CLAIMS

1. A peptide ligand specific for the collagen binding site of membrane type 1 metalloprotease MT1-MMP, or a pharmaceutically acceptable salt thereof, comprising a polypeptide comprising at least three cysteine residues, separated by at least two loop sequences, and a non-aromatic molecular scaffold which forms covalent bonds with the cysteine residues of the polypeptide such that at least two polypeptide loops are formed on the molecular scaffold, wherein the peptide ligand comprises an amino acid sequence selected from:

C_i-P-F/I/Y-D/S-W-H-T-C_{ii}-L-F-G-D/E-Y-T/S-C_{iii} (SEQ ID NO: 1); or

CPYSWETCLFGDYRC (SEQ ID NO: 2);

wherein C_i, C_{ii} and C_{iii} represent first, second and third cysteine residues, respectively.

2. The peptide ligand or pharmaceutically acceptable salt thereof as defined in claim 1, wherein the amino acid sequence of C_i-P-F/I/Y-D/S-W-H-T-C_{ii}-L-F-G-D/E-Y-T/S-C_{iii} (SEQ ID NO: 1) is selected from:

CPFDWHTCLFGDYTC (SEQ ID NO: 3);
CPFDWHTCLFGEYSC (SEQ ID NO: 4);
CPIDWHTCLFGDYTC (SEQ ID NO: 5);
CPFSWHTCLFGEYSC (SEQ ID NO: 6):
CPFSWHTCLFGDYTC (SEQ ID NO: 7);
CPISWHTCLFGDYSC (SEQ ID NO: 8); and
CPYSWHTCLFGDYSC (SEQ ID NO: 9).

3. The peptide ligand or pharmaceutically acceptable salt thereof as defined in claim 1, wherein the peptide ligand comprises an amino acid sequence selected from:

A-(SEQ ID NO: 2)-A (BCY1026);
A-(SEQ ID NO: 3)-A (BCY1057);
A-(SEQ ID NO: 4)-A (BCY1065);
A-(SEQ ID NO: 5)-A (BCY1067);
A-(SEQ ID NO: 6)-A (BCY1073);
A-(SEQ ID NO: 7)-A (BCY1074);
A-(SEQ ID NO: 8)-A (BCY1075); and
A-(SEQ ID NO: 9)-A (BCY1076).

4. The peptide ligand or pharmaceutically acceptable salt thereof as defined in claim 1 or claim 2, wherein the molecular scaffold is TATA.

5. The peptide ligand or pharmaceutically acceptable salt thereof as defined in claim 4, wherein the molecular scaffold is TATA and the peptide ligand comprises an amino acid sequence selected from:

A-(SEQ ID NO: 2)-A (BCY1026);
A-(SEQ ID NO: 3)-A (BCY1057);
A-(SEQ ID NO: 4)-A (BCY1065);
A-(SEQ ID NO: 5)-A (BCY1067);
A-(SEQ ID NO: 6)-A (BCY1073);
A-(SEQ ID NO: 7)-A (BCY1074);
A-(SEQ ID NO: 8)-A (BCY1075); and
A-(SEQ ID NO: 9)-A (BCY1076).

6. The peptide ligand or pharmaceutically acceptable salt thereof as defined in any one of claims 1 to 5, wherein the pharmaceutically acceptable salt is selected from the free acid or the sodium, potassium, calcium, ammonium salt.

7. The peptide ligand or pharmaceutically acceptable salt thereof as defined in any one of claims 1 to 6, wherein the MT1-MMP is human MT1-MMP.

8. A drug conjugate comprising a peptide ligand or pharmaceutically acceptable salt thereof as defined in any one of claims 1 to 7, conjugated to one or more effector and/or functional groups.

9. The drug conjugate as defined in claim 8, conjugated to one or more cytotoxic agents.

10. The drug conjugate as defined in claim 9, wherein said cytotoxic agent is selected from MMAE or DM1.

11. The drug conjugate as defined in claim 8, wherein the one or more effector and/or functional group is a metal chelator.

12. The drug conjugate as defined in claim 11, wherein the metal chelator is complexed to a metal radioisotope.

13. The drug conjugate as defined in claim 12, wherein the metal radioisotope is selected from ^{64}Cu, ^{67}Ga, ^{177}Lu, ^{90}Y, and ^{123}Bi.

14. A pharmaceutical composition which comprises the peptide ligand or pharmaceutically acceptable salt thereof of any one of claims 1 to 6 or the drug conjugate of any one of claims 8 to 13, in combination with one or more pharmaceutically acceptable excipients.

15. The pharmaceutical composition as defined in claim 14, which additionally comprises one or more therapeutic agents.

16. The drug conjugate as defined in any one of claims 8 to 13, for use in therapy.

17. Use of the drug conjugate as defined in any one of claims 8 to 13 in the manufacture of a medicament for suppressing or treating a solid tumour cancer.

18. The use of drug conjugate as defined in claim 17, wherein the solid tumour cancer is a non-small cell lung carcinomas.